Peer-reviewed veterinary case report
New metaflumizone plus amitraz spot-on treats demodectic mange in dogs
By Fourie, L J et al.·Published in Veterinary parasitology·2007·ClinVet International·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of a novel formulation of metaflumizone plus amitraz for the treatment of demodectic mange in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with demodectic mange, a skin condition caused by mites, were treated with a new topical medication that combines metaflumizone and amitraz. The treatment was given either once a month or every two weeks over three months. Both treatment schedules significantly reduced the number of mites, with over 94% reduction for the monthly group and over 99% for the bi-weekly group. By the end of the study, 42.9% of the dogs on the monthly treatment and 62.5% on the bi-weekly treatment had no detectable mites, showing that the new formulation was effective in treating this condition.
People also search for: dog demodectic mange treatment · metaflumizone amitraz for dogs · how to treat dog skin mites
Abstract
A novel spot-on formulation containing metaflumizone plus amitraz (ProMeris/ProMeris Duo for Dogs, Fort Dodge Animal Health, Overland Park, KS) was evaluated for efficacy against demodectic mange mites in naturally infested dogs. Sixteen dogs were allocated to two equal groups and individually housed. Eight of the dogs were treated topically with metaflumizone plus amitraz at the proposed minimum dose rate (20mg/kg of each of metaflumizone and amitraz, 0.133ml/kg) on Days 0, 28, and 56. The other eight were treated with metaflumizone plus amitraz at the proposed minimum dose rate on Days 0, 14, 28, 42, 56, and 70. Mite numbers were estimated from skin scrapings taken on Days -3 to -1, 28, 56, and 84. Clinical signs of mange and the extent of demodectic lesions on each dog were evaluated when skin scrapings were conducted. Efficacy of the treatment was based on a reduction in mite numbers and an assessment of the clinical signs associated with canine demodectic mange. Treatment at monthly or two-weekly intervals for 3 months resulted in a rapid reduction in mite numbers (>94 and >99% for the monthly and two-weekly treatments, respectively) and an improvement in clinical signs. Success rates, based on zero mite counts in skin scrapings at Day 84 were 42.9 and 62.5% of dogs for the monthly and two-weekly regimens, respectively.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17923331/